Bio-Techne (NASDAQ:TECH) Surprises With Strong Q4, Stock Soars
Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 9% year on year to $297 million. Its non-GAAP profit of $0.42 per share was 9.3% above analysts’ consensus estimates.